$-0.02
(Market cap
$541 Mln
Revenue (TTM)
$223 Mln
P/E Ratio
--
P/B Ratio
7.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.2 %
-
ROCE
-- %
-
Industry P/E
44.41
-
EV/EBITDA
1140.8
-
Debt to Equity
0.5
-
Book Value
$--
-
EPS
$-0
-
Face value
--
-
Shares outstanding
200,368,974
10 Years Aggregate
CFO
$-437.24 Mln
EBITDA
$-527.05 Mln
Net Profit
$-541.28 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cerus (CERS)
| 32.0 | 40.9 | 12.9 | 117.6 | 13.1 | -14.1 | -6.3 |
|
BSE Sensex
| -10.9 | -4.9 | -8.9 | -7.6 | 6.9 | 8.3 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Cerus (CERS)
| 33.8 | -28.5 | -40.8 | -46.4 | -1.6 | 64.0 | -16.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cerus (CERS)
|
2.7 | 541.0 | 222.8 | -9.6 | -7.5 | -14.8 | -- | 7.8 |
| 7.9 | 5,216.3 | 6,552.2 | -551.4 | -4.3 | -9.9 | -- | 1.0 | |
| 267.4 | 7,156.9 | 2,589.9 | 168.8 | 21.4 | 2.5 | 44.4 | 1.0 | |
| 45.2 | 6,483.3 | 3,458.5 | -11.6 | 2.6 | -0.5 | -- | 2.7 | |
| 137.7 | 8,216.9 | 551.4 | -189.3 | -15.6 | -26.3 | -- | 12.2 | |
| 94.5 | 6,047.7 | 1,546.2 | 279.0 | 15.0 | 23.9 | 22.2 | 5.0 | |
| 178.5 | 9,363.6 | 1,558.5 | 76.3 | 19.6 | 9.5 | 44.3 | 11.8 | |
| 63.7 | 3,804.2 | 1,542.8 | 139.3 | 12.1 | 8.8 | 27.5 | 2.2 | |
| 328.8 | 12,843.7 | 1,454.3 | 171.1 | 11.1 | 12.1 | 75.2 | 8.7 | |
| 112.7 | 6,121.4 | 763.3 | 51.4 | 11.7 | 2.5 | 119.3 | 2.8 |
Shareholding Pattern
View DetailsAbout Cerus (CERS)
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling... biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California. Address: 1220 Concord Avenue, Concord, CA, United States, 94520 Read more
-
President, CEO & Director
Mr. William M. Greenman
-
President, CEO & Director
Mr. William M. Greenman
-
Headquarters
Concord, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Cerus (CERS)
What is the current share price of Cerus Corporation (CERS) Today?
The share price of Cerus Corporation (CERS) is $2.72 (NASDAQ) as of 22-May-2026 11:39 EDT. Cerus Corporation (CERS) has given a return of 13.1% in the last 3 years.
What is the current PB & PE ratio of Cerus Corporation (CERS)?
Since, TTM earnings of Cerus Corporation (CERS) is negative, P/E ratio is not available.
The P/B ratio of Cerus Corporation (CERS) is 7.77 times as on 20-May-2026, a 168 premium to its peers’ median range of 2.90 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-25.32
|
6.16
|
|
2024
|
-13.59
|
5.06
|
|
2023
|
-10.44
|
7.43
|
|
2022
|
-15.13
|
9.58
|
|
2021
|
-21.68
|
13.93
|
What is the 52 Week High and Low of Cerus Corporation (CERS)?
The 52-week high and low of Cerus Corporation (CERS) are Rs 3.15 and Rs 1.15 as of 22-May-2026.
What is the market cap of Cerus Corporation (CERS)?
Cerus Corporation (CERS) has a market capitalisation of $ 541 Mln as on 20-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Cerus Corporation (CERS)?
Before investing in Cerus Corporation (CERS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.